Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Determination of rosmarinic acid and its N-substituted analog A1 in rat plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in pharmacokinetics
  • +2
  • Shujie Fu,
  • Qinglang Zhang,
  • Shiyu Zhang,
  • Weizhe Jiang,
  • Minjie Jiang
Shujie Fu
Guangxi Medical University
Author Profile
Qinglang Zhang
GuangXi University of Chinese Medicine
Author Profile
Shiyu Zhang
GuangXi University of Chinese Medicine
Author Profile
Weizhe Jiang
Guangxi Medical University
Author Profile
Minjie Jiang
GuangXi University of Chinese Medicine

Corresponding Author:[email protected]

Author Profile

Abstract

The researcher will introduce the way of effective liquid chromatography tandem mass spectrometric method (HPLC-MS) which is quick, sensitive, and alternative to determine the (E)-3-(3,4-dihydroxyphenyl) -2-(3-(3,4-dihydroxyphenyl)acrylamido)propanoic acid (A1) and rosmarinic acid (RA) of the plasma in rats. The analyses were divided into a C18 column (1.9 μm, 2.1 mm × 100 mm) with a security guard C18 column (5 μm, 2.1 mm × 10 mm) and a triple-quadrupole mass spectrometry with an electrospray ionization (ESI) ion-source generates ions. With Pseudoephedrine hydrochloride being a standard, the sample pretreatment is relevant to the one-step protein precipitation with isopropanol: ethyl acetate (v/v, 20:80). This method presented a linear relationship within ranges of the concentration of 5–750 ng/ml for RA and A1. Relative standard deviations (RSD) in daily courses stood less than 15% and the relative errors (RE) registered within 15%. The means adopted in this research makes the RA’s and A1’s unambiguous quantification and identification and in vivo possible. And this study can be the first one to focus on determining the A1 and RA of rat plasma with administration orally. The results served as a significant basis to evaluate the medicine’s applications in the clinic.
24 Feb 2023Submitted to Rapid Communications in Mass Spectrometry
25 Feb 2023Submission Checks Completed
25 Feb 2023Assigned to Editor
25 Feb 2023Review(s) Completed, Editorial Evaluation Pending
28 Feb 2023Reviewer(s) Assigned
11 Apr 2023Editorial Decision: Revise Major
04 May 20231st Revision Received
04 May 2023Submission Checks Completed
04 May 2023Assigned to Editor
04 May 2023Review(s) Completed, Editorial Evaluation Pending
06 May 2023Reviewer(s) Assigned
29 May 2023Editorial Decision: Revise Minor
01 Jun 20232nd Revision Received
03 Jun 2023Submission Checks Completed
03 Jun 2023Assigned to Editor
03 Jun 2023Review(s) Completed, Editorial Evaluation Pending
03 Jun 2023Reviewer(s) Assigned
13 Jun 2023Editorial Decision: Accept